Identification of FES as a Novel Radiosensitizing Target in Human Cancers

Byoung Hyuck Kim1,2, Yong Joon Kim3,4, Myung-Ho Kim4

  • 1Department of Radiation Oncology, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.

Abstract

Insights

Inhibiting the FES kinase sensitizes cancer cells to radiation therapy by increasing DNA damage and apoptosis. This finding offers a new strategy for overcoming tumor radioresistance and developing novel radiosensitizers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy Research

Background:

  • Tumor radioresistance remains a significant challenge in cancer treatment.
  • Identifying novel targets for synergistic drug-radiation combinations is crucial for improving therapeutic outcomes.

Purpose of the Study:

  • To identify a radiation-specific kinase that, upon inhibition, exhibits synergistic toxicity with radiation.
  • To find a kinase that is not essential for cell survival in the absence of radiation, minimizing side effects.

Main Methods:

  • Conducted a human kinome siRNA library screen in A549 cells followed by irradiation.
  • Examined the radiosensitizing effects and underlying mechanisms of the identified target gene.
  • Validated findings in lung and pancreatic cancer cell lines and an in vivo mouse xenograft model.

Main Results:

  • Identified FES (FEline Sarcoma oncogene) tyrosine kinase as a radiosensitizing target.
  • FES knockdown significantly decreased cell viability and clonogenic survival post-irradiation, with no effect on proliferation without radiation.
  • FES depletion enhanced radiation-induced apoptosis, DNA damage, G2-M arrest, and mitotic catastrophe, involving reactive oxygen species, S6K, MDM2, and p53 pathways.

Conclusions:

  • Inhibition of FES is a potential strategy for inducing cancer radiosensitization.
  • This study provides a basis for developing novel FES-targeted radiosensitizers to overcome tumor radioresistance.